Discovery Hub
Gamma1 heavy chain humanized (1-450) [VH (Homo sapiens IGHV4-31*01 (89.9%) -(IGHD) -IGHJ4*01 (92.9%), CDR-IMGT [9.7.13] (26-34.52-58.97-109)) (1-120) -Homo sapiens IGHG1*01 (100%), G1m17,1 CH1 K120, D12, L14 (CH1 K120 (217) (121-218), hinge 1-15 (219-233), CH2 (234-343), CH3 D12 (359), L14 (361) (344-448), CHS (449-450)) (121-450)], (223-214')-disulfide with kappa light chain humanized (1'-214') [V-KAPPA (Homo sapiens IGKV1-12*01 (85.3%)-IGKJ2*01 (100%), CDR-IMGT [6.3.9] (27-32.50-52.89-97)) (1'-107') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (229-229'':232-232'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, derived from the cell line CHO-K1,glycoform alfa

Gamma1 heavy chain humanized (1-450) [VH (Homo sapiens IGHV4-3101 (89.9%) -(IGHD) -IGHJ401 (92.9%), CDR-IMGT [9.7.13] (26-34.52-58.97-109)) (1-120) -Homo sapiens IGHG101 (100%), G1m17,1 CH1 K120, D12, L14 (CH1 K120 (217) (121-218), hinge 1-15 (219-233), CH2 (234-343), CH3 D12 (359), L14 (361) (344-448), CHS (449-450)) (121-450)], (223-214')-disulfide with kappa light chain humanized (1'-214') [V-KAPPA (Homo sapiens IGKV1-1201 (85.3%)-IGKJ201 (100%), CDR-IMGT [6.3.9] (27-32.50-52.89-97)) (1'-107') -Homo sapiens IGKC01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (229-229'':232-232'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, derived from the cell line CHO-K1,glycoform alfa

Nasopharyngeal Cancinoma (NPC)

Hummingbird Biosciencemonoclonal_antibodyPhase 1/2Active

CCC

48/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 33/ 100
Competitive Position: 95/ 100

Competitive context

43 Active assets in the Nasopharyngeal Cancinoma (NPC) cohort.

Asset / Sponsor	Phase	Rating
Eloxatin National Cancer Institute (NCI)	Phase 2	BB
Irinotecan M.D. Anderson Cancer Center	Phase 2	B
Ipilimumab Xencor, Inc.	Phase 2	B
Immunoglobulin G1 [de-448-lysine], anti-(human epidermal growth factor receptor) (human-mouse monoclonal C225 ?1-chain) fusion protein with peptide linker (GGGGS)2 fusion protein with immunoglobulin anti-(human epidermal growth factor receptor HER3) (human clone HER3.H3 single-chain variable fragment VH-(GGGGS)3-VL), complex with human-mouse monoclonal C225 ?-chain, dimer, 214??,214???,222,222?,228,228?,231,231?-octakis(thioether) with (2S)-N-(carboxymethyl)-2-(3-mercapto-2,5-dioxo-1-pyrrolidinyl)-?-alanylglycylglycyl-L-phenylalanyl-N-[[(1S)-2-[[(1S,9S)-9-ethyl-5-fluoro-2,3,9,10,13,15-hexahydro-9-hydroxy-4-methyl-10,13-dioxo-1H,12H-benzo[de]pyrano[3?,4?:6,7]indolizino[1,2-b]quinolin-1-yl]amino]-1-methyl-2-oxoethoxy]methyl]glycinamide Sichuan Baili Pharmaceutical Co., Ltd.	Phase 2	B
[18f]f-resca-rt4 RenJi Hospital	Phase 2/3	B

View all 50 →

Same molecule, other indications

Gamma1 heavy chain humanized (1-450) [VH (Homo sapiens IGHV4-31*01 (89.9%) -(IGHD) -IGHJ4*01 (92.9%), CDR-IMGT [9.7.13] (26-34.52-58.97-109)) (1-120) -Homo sapiens IGHG1*01 (100%), G1m17,1 CH1 K120, D12, L14 (CH1 K120 (217) (121-218), hinge 1-15 (219-233), CH2 (234-343), CH3 D12 (359), L14 (361) (344-448), CHS (449-450)) (121-450)], (223-214')-disulfide with kappa light chain humanized (1'-214') [V-KAPPA (Homo sapiens IGKV1-12*01 (85.3%)-IGKJ2*01 (100%), CDR-IMGT [6.3.9] (27-32.50-52.89-97)) (1'-107') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (229-229'':232-232'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, derived from the cell line CHO-K1,glycoform alfa is also rated in:

head and neck squamous cell carcinomaDormant

CCC

Indicative ·

48 / 100

View asset →

esophageal squamous cell carcinomaDormant

CCC

Indicative ·

48 / 100

View asset →

skin squamous cell carcinomaDormant

CCC